Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEsiR-ACS Trial
NCT07799779Phase 4Not yet recruiting
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of inclisiran in acute coronary syndrome (ACS) (2 arms), sponsored by Seoul National University Bundang Hospital. Primary endpoint: Change in Minimal Fibrous Cap Thickness at 12 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
inclisiran
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT07799779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07799779.